Galapagos Price to Sales Ratio 2013-2021 | GLPG

Historical PS ratio values for Galapagos (GLPG) over the last 10 years. The current P/S ratio for Galapagos as of January 19, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Galapagos P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-01-20 56.46 6.19
2021-09-30 52.61 $9.13 5.77
2021-06-30 68.89 $10.54 6.54
2021-03-31 77.09 $9.72 7.93
2020-12-31 98.98 $9.30 10.64
2020-09-30 141.91 $9.12 15.55
2020-06-30 197.29 $18.51 10.66
2020-03-31 195.92 $17.90 10.95
2019-12-31 206.83 $16.93 12.22
2019-09-30 152.66 $16.72 9.13
2019-06-30 128.93 $7.03 18.33
2019-03-31 117.78 $6.96 16.91
2018-12-31 91.74 $7.20 12.75
2018-09-30 112.43 $4.66 24.14
2018-06-30 92.18 $3.31 27.88
2018-03-31 99.76 $2.35 42.39
2017-09-30 101.75 $1.69 60.28
2017-03-31 86.19 $1.99 43.29
2016-03-31 41.82 $1.66 25.26
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.590B $0.606B
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.655B 9.08
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.351B 19.22
Biohaven Pharmaceutical Holding (BHVN) United States $7.535B 0.00
Emergent Biosolutions (EBS) United States $2.453B 8.82
Arcus Biosciences (RCUS) United States $2.353B 0.00
Myovant Sciences (MYOV) United Kingdom $1.344B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.156B 0.00
Zymeworks (ZYME) Canada $0.627B 0.00
Ambrx Biopharma (AMAM) United States $0.207B 0.00
SQZ Biotechnologies (SQZ) United States $0.207B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81